Page last updated: 2024-08-22

vidarabine and curcumin

vidarabine has been researched along with curcumin in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M	1
Everett, PC; Lerner, A; Makkinje, A; Meyers, JA; Rabbi, M	1
Bartholomé, K; Buchner, M; Burger, M; Chevalier, N; Dierks, C; Fuchs, S; Gribben, JG; Jumaa, H; Pfeifer, D; Prinz, G; Timmer, J; Vallat, L; Veelken, H; Zirlik, K	1

Trials

1 trial(s) available for vidarabine and curcumin

Article	Year
Preclinical assessment of curcumin as a potential therapy for B-CLL. American journal of hematology, 2007, Volume: 82, Issue:1 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Curcumin; Cyclic Nucleotide Phosphodiesterases, Type 4; Dexamethasone; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; NF-kappa B; NF-kappaB-Inducing Kinase; PPAR gamma; Protein Serine-Threonine Kinases; Rolipram; Signal Transduction; Tumor Cells, Cultured; Vidarabine; Vincristine	2007

Article

Year

Preclinical assessment of curcumin as a potential therapy for B-CLL.

American journal of hematology, 2007, Volume: 82, Issue:1

Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Curcumin; Cyclic Nucleotide Phosphodiesterases, Type 4; Dexamethasone; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; NF-kappa B; NF-kappaB-Inducing Kinase; PPAR gamma; Protein Serine-Threonine Kinases; Rolipram; Signal Transduction; Tumor Cells, Cultured; Vidarabine; Vincristine

2007

Other Studies

2 other study(ies) available for vidarabine and curcumin

Article	Year
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3 Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries	2023
Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer research, 2009, Jul-01, Volume: 69, Issue:13 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Caspase 3; Cell Line, Tumor; Curcumin; Gene Expression Profiling; Humans; Immunoglobulin Variable Region; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Staging; Oxazines; Phosphorylation; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Syk Kinase; Vidarabine	2009

Article

Year

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.

Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023

Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.

Cancer research, 2009, Jul-01, Volume: 69, Issue:13

Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Caspase 3; Cell Line, Tumor; Curcumin; Gene Expression Profiling; Humans; Immunoglobulin Variable Region; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Staging; Oxazines; Phosphorylation; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Syk Kinase; Vidarabine

2009